**Screening: Therapeutic Effectiveness Study**

**Inclusion Criteria**

1. Aged between 6 and 59 months (5 years)

2. Weight ≥ 5Kg

3. P.falciparum monoinfection with a parasite density between 2,000 and 200,000 asexual parasites per microliter of blood

4. Axillary temperature 37.5°C during the visit to the health facility or a history of fever in the past 24 hours

5. Hemoglobin ≥ 8.0g/dl

6. Easy access to the health facility, and the ability to report to the health facility on evaluation days during the 28-day period (42 days in the case of DP)

7. Parental or guardian consent, after explanation of the purpose of the evaluation

**Exclusion Criteria**

1. Presence of any danger signs or severe/complicated malaria

2. Presence of pneumonia or bronchopneumonia

Respiratory rate of:

>50 in children under 12 months of age

>40 in children aged 12-59 months

>20 in children aged 60-108 months

3. Severe malnutrition (Z-score < -3)

4. In the last 14 days, has taken an antimalarial or an antibiotic that may affect the assessment such as cotrimoxazole, tetracycline, or doxycycline

5. Mixed parasitemia (P.vivax, P.malariae, P.ovale)

6. History of hypersensitivity or allergy to the drug